Short Interest in Orion OYJ Unsponsored ADR (OTCMKTS:ORINY) Increases By 2,800.0%

Key Points

• Short interest in Orion OYJ Unsponsored ADR increased dramatically by 2,800.0% in July, rising from 100 shares to 2,900 shares.
• The stock price has remained relatively stable, trading at $38.43, with a market capitalization of $10.85 billion.
• Orion OYJ reported $0.33 EPS and $472.57 million in revenue for the last quarter, with analysts predicting an EPS of 1.18 for the current year.

Orion OYJ Unsponsored ADR (OTCMKTS:ORINY - Get Free Report) saw a significant growth in short interest in July. As of July 31st, there was short interest totaling 2,900 shares, agrowthof2,800.0% from the July 15th total of 100 shares. Approximately0.0% of the company's stock are short sold. Based on an average trading volume of 1,600 shares, the short-interest ratio is currently 1.8 days. Based on an average trading volume of 1,600 shares, the short-interest ratio is currently 1.8 days. Approximately0.0% of the company's stock are short sold.

Orion OYJ Price Performance

Shares of Orion OYJ stock remained flat at $38.43 during trading hours on Thursday. The stock had a trading volume of 81 shares, compared to its average volume of 556. The stock has a fifty day moving average of $38.27 and a 200 day moving average of $32.44. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.05 and a current ratio of 1.86. The stock has a market cap of $10.85 billion, a P/E ratio of 26.14 and a beta of 0.10. Orion OYJ has a 12 month low of $21.95 and a 12 month high of $41.60.

Orion OYJ (OTCMKTS:ORINY - Get Free Report) last posted its quarterly earnings results on Friday, July 18th. The company reported $0.33 EPS for the quarter. The business had revenue of $472.57 million during the quarter. Orion OYJ had a return on equity of 38.68% and a net margin of 22.61%. As a group, equities research analysts predict that Orion OYJ will post 1.18 EPS for the current year.

Orion OYJ Company Profile

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson's disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.